ECE2008 Poster Presentations Neuroendocrinology (107 abstracts)
Effect of hyperprolactinemia in male patients consulting for sexual dysfunction
Corona Giovanni 1 , Edoardo Mannuci 2 , Alessandra Fisher 1 , Francesco Lotti 1 , Valdo Ricca 3 , Giancarlo Balercia 4 , Luisa Petrone 1 , Gianni Forti 1 & Mario Maggi 1
1Andrology Unit, University of Florence, Florence, Italy; 2Diabetes Section Geriatric Unit, University of Florence, Florence, Italy; 3Pychiatric Unit, University of Florence, Florence, Italy; 4Endocrinology Unit4, Polytechnic University of Marche, Ancona, Italy.
Objectives: The physiological role of prolactin in male sexual function has not been completely clarified. Aim of this study is the assessment of clinical features and of conditions associated with hyperprolactinemia in male patients consulting for sexual dysfunction.
Design and methods: A consecutive series of 2146 (mean age 52.2±12.8 years) male patients with sexual dysfunction was studied. Several hormonal and biochemical parameters were studied along with validated structured interviews (ANDROTEST and SIEDY). Mild hyperprolactinemia (MHPRL; PRL levels 420–735 mU/l or 20–35 ng/ml) and severe hyperprolactinemia (SHPRL, PRL levels >735 mU/l, 35 ng/ml) were considered.
Results: MHPRL and SHPRL were found in 69 (3.3%) and in 32 (1.5%) patients respectively. Mean age and the prevalence of gynecomastia were similar in the two groups and in subjects with normal prolactin values. MHPRL was not confirmed in almost one half of the patients, after repetitive venous sampling. Hyperprolactinemia was associated with the current use of antidepressants, antipsychotic drugs and benzamides. SHPRL was also associated with hypoactive sexual desire (HSD), elevated TSH, and hypogonadism. The association between HSD and SHPRL was confirmed after adjustment for testosterone, TSH levels and use of psychotropic drugs (HR=8.60 (3.85–19.23); P<0.0001). In a 6 -months follow up of patients with SHPRL testosterone levels and sexual desire were significantly improved by the treatment.
Conclusions: Our data indicate that SHPRL, but not MHPRL, is a relevant determinant of HSD. Gynecomastia does not help in recognising hyperprolactinemic subjects, while the use of psychotropic medications and HSD are possible markers of disease. In case of MHPRL, repetitive venous sampling is strongly encouraged.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more